Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04368988
Recruitment Status : Recruiting
First Posted : April 30, 2020
Last Update Posted : May 27, 2020
Sponsor:
Information provided by (Responsible Party):
Novavax

Brief Summary:
For Phase 1 only. Additional information will be provided if Phase 2 is implemented. 2019nCoV-101 is a 2-part, randomized, observer-blinded, placebo-controlled, Phase 1/2 trial designed to evaluate the immunogenicity and safety of SARS-CoV-2 rS nanoparticle vaccine with or without Matrix-M adjuvant in healthy participants ≥ 18 to 59 (inclusive) years of age. The study will be conducted in 2 parts. In Part 1, at least 1 and up to two SARS-CoV-2 rS constructs will be evaluated in up to 2 cohorts, which may be enrolled in parallel. An interim analysis of Part 1 safety and immunogenicity data will be performed prior to an optional expansion to Part 2.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: SARS-CoV-2 rS Other: Matrix-M Adjuvant Other: NSS Saline Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 131 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects
Actual Study Start Date : May 25, 2020
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : July 31, 2021

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo - Saline
Other: NSS Saline Placebo
Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment assigned (ie, saline).

Experimental: SARS-CoV-2 rS - 25 μg without Matrix-M
SARS-CoV-2 rS - 25 μg without Matrix-M
Biological: SARS-CoV-2 rS
Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment.

Experimental: SARS-CoV-2 rS - 5 μg with 50 μg Matrix-M
SARS-CoV-2 rS - 5 μg with 50 μg Matrix-M
Biological: SARS-CoV-2 rS
Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment.

Other: Matrix-M Adjuvant
Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment assigned.
Other Name: Adjuvant

Experimental: SARS-CoV-2 rS - 25 μg with 50 μg Matrix-M
SARS-CoV-2 rS - 25 μg with 50 μg Matrix-M
Biological: SARS-CoV-2 rS
Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment.

Other: Matrix-M Adjuvant
Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment assigned.
Other Name: Adjuvant

Experimental: SARS-CoV-2 rS - 25 μg with 50 μg Matrix-M followed by Placebo
SARS-CoV-2 rS - 25 μg with 50 μg Matrix-M followed by Placebo
Biological: SARS-CoV-2 rS
Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment.

Other: Matrix-M Adjuvant
Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment assigned.
Other Name: Adjuvant

Other: NSS Saline Placebo
Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment assigned (ie, saline).




Primary Outcome Measures :
  1. Subjects with solicited AEs - Phase 1 [ Time Frame: 28 days ]
    Numbers and percentages (with 95% CIs) of subjects with solicited AEs (local, systemic) for 7 days following each primary vaccination (Days 0, 21) by severity score, duration, and peak intensity. In the case of no reactogenicity, a toxicity score of zero (0) will be applied.

  2. Safety Laboratory Values (serum chemistry, hematology) - Phase 1 [ Time Frame: 28 days ]
    Safety laboratory values (serum chemistry, hematology) by FDA toxicity scoring (absolute and change from baseline where identified) at 7 days after each vaccination.

  3. Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) - Phase 1 [ Time Frame: 35 days ]
    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA at Day 21 and Day 35. Derived/calculated endpoints based on these data will include geometric mean ELISA units, geometric mean fold rise, and seroconversion rate (proportion of subjects with ≥4-fold rises in ELISA units).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria (Phase 1):

  • Healthy adult males or females between 18 and 59 years of age, inclusive, at screening (Phase 1). Healthy status will be determined by the investigator based on medical history, clinical laboratory results, vital sign measurements, and physical examination at screening.
  • The subject has a body mass index 17 to 40 kg/m2, inclusive, at screening.
  • Willing and able to give informed consent prior to study enrollment and comply with study procedures.
  • Female subjects of childbearing potential (defined as any female who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months or documented plasma follicle-stimulating hormone level ≥40 mIU/mL]) must agree to be heterosexually inactive from at least 21 days prior to enrollment and through 6 months after the last vaccination OR agree to consistently use any of the described methods of contraception from at least 21 days prior to enrollment and through 6 months after the last vaccination.

Exclusion Criteria (Phase 1):

  • Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care, inclusive of changes in medication in the past 2 months indicating that chronic illness/disease is not stable (at the discretion of the investigator). This includes any current workup of undiagnosed illness that could lead to a new condition.
  • Chronic disease inclusive of: a) hypertension uncontrolled for age according to JNC 8 guidelines; b) congestive heart failure by NYHA functional classification of greater or equal to II; c) chronic obstructive pulmonary disease by GOLD classification of greater or equal to 2; d) recent (within 6 months prior to first study vaccination) exacerbation of coronary artery disease as manifested by cardiac intervention, addition of new cardiac medications for control of symptoms, or unstable angina; e) asthma (diagnosed by spirometry showing reversibility of disease and must meet at least the Step 1 classification with current prescription/use of medications to control symptoms); f) diabetes requiring use of medicine (insulin or oral) or not controlled with diet.
  • Participation in research involving an investigational product (drug/biologic/device) within 45 days prior to first study vaccination.
  • History of a confirmed diagnosis of SARS or COVID-19 disease (confirmed by a specific test for each disease) or known exposure to a SARS-CoV-2 positive confirmed close contact (eg, family member, housemate, daycare provider, aged parent requiring care), at the discretion of the investigator.
  • Currently working in an occupation with a high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response personnel).
  • Currently taking any product (investigational or off-label) for prevention of COVID-19 disease.
  • Positive rapid test for SARS-CoV-2 (ELISA or PCR) at screening or prior to first vaccination (if available).
  • Received influenza vaccination within 14 days prior to first study vaccination, or any other vaccine within 4 weeks prior to first study vaccination.
  • Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital).
  • Chronic administration (defined as more than 14 continuous days) of immunosuppressant, systemic glucocorticosteroids, or other immune-modifying drugs within 4 months prior to first study vaccination or anticipation of the need for immunosuppressive treatment within 6 months after last vaccination.
  • Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination.
  • Any acute illness concurrent or within 14 days prior to first study vaccination (medical history and/or physical examination) or documented temperature of >38°C during this period. This includes respiratory or constitutional symptoms consistent with SARS-CoV-2 (COVID-19) exposure (ie, cough, sore throat, difficulty breathing)
  • Known disturbance of coagulation (iatrogenic or congenital). NOTE: The use of ≤325 mg of aspirin per day as prophylaxis is permitted, but the use of other platelet aggregation inhibitors, thrombin inhibitors, Factor Xa inhibitors, or warfarin derivatives is exclusionary, regardless of bleeding history, because these imply treatment or prophylaxis of known cardiac or vascular disease.
  • Evidence of Hepatitis B or C or HIV by laboratory testing.
  • A positive test result for drugs of abuse (except a positive test result associated with prescription medication that has been reviewed and approved by the investigator) or alcohol at screening.
  • Any neurological disease or history of significant neurological disorder (eg, meningitis, seizures, multiple sclerosis, vasculitis, migraines, Guillain-Barré syndrome [genetic/congenital or acquired]).
  • Active cancer (malignancy) within 5 years prior to first study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma, at the discretion of the investigator)
  • Vital sign (blood pressure, pulse, temperature) abnormalities of toxicity grade >1
  • Clinical laboratory abnormalities of toxicity grade >1 for selected serum chemistry and hematology parameters
  • Any known allergies to products contained in the investigational product or latex allergy.
  • Women who are pregnant, breastfeeding or who plan to become pregnant during the study.
  • History of alcohol abuse or drug addiction within one year prior to the first study vaccination.
  • Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
  • Study team member or first-degree relative of any study team member (inclusive of sponsor, PPD, and site personnel involved in the study).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04368988


Contacts
Layout table for location contacts
Contact: Biljana Georgievska 61 3 8593 9817 B.Georgievska@nucleusnetwork.com.au

Locations
Layout table for location information
Australia, Queensland
Investigational Research Site 1 Recruiting
Herston, Queensland, Australia, 4006
Contact: Biljana Georgievska    61 3 8593 9817    B.Georgievska@nucleusnetwork.com.au   
Australia, Victoria
Investigational Research Site 2 Recruiting
Melbourne, Victoria, Australia, 3181
Contact: Biljana Georgievska    61 3 8593 9817    B.Georgievska@nucleusnetwork.com.au   
Sponsors and Collaborators
Novavax
Layout table for additonal information
Responsible Party: Novavax
ClinicalTrials.gov Identifier: NCT04368988    
Other Study ID Numbers: 2019nCoV-101
First Posted: April 30, 2020    Key Record Dates
Last Update Posted: May 27, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No